Table 3.
Factors associated with disease-free survival and overall survival in the cohort of propensity score-matched patients with ypT0-3N0 rectal cancer
| Disease-free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age, years | 0.038 | 0.382 | 0.025 | 0.269 | ||||
| < 70 | 1 | 1 | 1 | 1 | ||||
| ≥ 70 | 1.873 (1.036–3.386) | 1.324 (0.706–2.483) | 2.513 (1.125–5.609) | 1.598 (0.695–3.673) | ||||
| Sex | 0.220 | 0.030 | 0.075 | |||||
| Female | 1 | 1 | 1 | 1 | ||||
| Male | 1.553 (0.769–3.138) | 4.951 (1.167–21.005) | 3.782 (0.875–16.352) | |||||
| Distance from AV (cm) | 0.511 | 0.416 | ||||||
| ≥ 10.0 | 1 | 1 | ||||||
| 5.0–9.9 | 0.669 (0.256–1.745) | 0.510 (0.146–1.784) | ||||||
| < 5.0 | 0.956 (0.383–2.391) | 0.897 (0.281–2.862) | ||||||
| Differentiation | 0.896 | 0.464 | ||||||
| Well | 1 | 1 | ||||||
| Moderate | 0.842 (0.411–1.726) | 0.579 (0.233–1.439) | ||||||
| Poor, mucinous | 0.871 (0.271–2.803) | 0.868 (0.220–3.432) | ||||||
| Pretreatment CEA (ng/mL) | 0.014 | 0.039 | 0.348 | |||||
| < 5 | 1 | 1 | 1 | |||||
| ≥ 5 | 2.075 (1.156–3.727) | 1.912 (1.033–3.540) | 1.461 (0.662–3.226) | |||||
| Surgical procedure | 0.039 | 0.339 | 0.033 | 0.225 | ||||
| LAR | 1 | 1 | 1 | 1 | ||||
| APR | 2.133 (1.038–4.384) | 1.465 (0.670–3.206) | 2.615 (1.082–6.319) | 1.764 (0.705–4.411) | ||||
| Stage | 0.003 | 0.019 | 0.002 | 0.007 | ||||
| ypT0 | 1 | 1 | 1 | 1 | ||||
| ypT1 | 4.239 (1.299–13.831) | 3.461 (1.017–11.778) | 10.163 (2.033–50.817) | 6.894 (1.343–35.381) | ||||
| ypT2 | 2.388 (1.040–5.485) | 1.893 (0.808–4.434) | 2.243 (0.555–9.059) | 1.647 (0.387–7.005) | ||||
| ypT3 | 4.438 (1.963–10.032) | 3.517 (1.528–8.093) | 7.533 (2.114–26.848) | 5.782 (1.588–21.051) | ||||
| LN dissected | 0.729 | 0.946 | ||||||
| ≥ 12 | 1 | 1 | ||||||
| < 12 | 0.901 (0.500–1.624) | 1.028 (0.467–2.259) | ||||||
| LVI/PNI | 0.294 | 0.591 | ||||||
| Negative | 1 | 1 | ||||||
| Positive | 2.149 (0.516–8.955) | 0.047 (0.000–3244.523) | ||||||
| Margin | <0.001 | 0.001 | <0.001 | 0.005 | ||||
| Negative | 1 | 1 | 1 | 1 | ||||
| Positive | 8.956 (3.131–25.613) | 7.193 (2.234–23.156) | 10.375 (3.022–35.623) | 7.035 (1.806–27.404) | ||||
| Mandard regression grade | 0.006 | 0.039 | ||||||
| Grade 1 | 1 | 1 | ||||||
| Grade 2 | 3.086 (1.319–7.222) | 5.268 (1.398–19.860) | ||||||
| Grade 3 | 4.542 (1.880–10.970) | 4.113 (0.920–18.379) | ||||||
| Grade 4 | 3.771 (1.263–11.261) | 8.159 (1.825–36.482) | ||||||
| Adjuvant chemotherapy | 0.688 | 0.655 | ||||||
| No | 1 | 1 | ||||||
| Yes | 1.129 (0.626–2.035) | 1.200 (0.539–2.669) | ||||||
HR hazard ratio, CI confidence interval, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection, LN lymph node, LVI lymphovascular invasion, PNI perineural invasion